Great Lakes Retirement Inc. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 7,014 shares of the company’s stock, valued at approximately $1,239,000.
Several other institutional investors have also modified their holdings of JNJ. DORCHESTER WEALTH MANAGEMENT Co lifted its stake in shares of Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P increased its holdings in shares of Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares in the last quarter. AMI Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 8.8% in the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares in the last quarter. Equitable Holdings Inc. increased its holdings in shares of Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd increased its holdings in shares of Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Trading Up 0.3 %
Shares of JNJ stock opened at $164.23 on Friday. The stock has a market cap of $426.79 billion, a price-to-earnings ratio of 34.36, a price-to-earnings-growth ratio of 2.80 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The firm’s 50 day moving average price is $160.73 and its two-hundred day moving average price is $163.98.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd were given a dividend of $1.19 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 99.58%.
Insider Transactions at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the stock. Citigroup assumed coverage on shares of Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price for the company. StockNews.com assumed coverage on shares of Johnson & Johnson in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. Credit Suisse Group raised their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. UBS Group assumed coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price for the company. Finally, Atlantic Securities dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $171.57.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 6/12 – 6/16
- Micron Building Goodwill In Asia, Near $2 Billion Investment
- Is Twilio On The Verge Of A Comeback?
- Broadcom: All-Time Highs But Still Good Value
- Leverage AI And Build A Fortress Portfolio With Adobe
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
